MarketPeel
Insider Trading Intelligence
BH

Benjamin Halladay

ESPR
CHIEF FINANCIAL OFFICER · ESPERION THERAPEUTICS, INC. · CIK 0001953943
FILING MIX · LIFETIME48%/52%
BUYS
10
SELLS
11
TOTAL VALUE
$119.6K
COMPANIES
1
ACTIVE SINCE
Dec 2022
HOLDINGS NOW
702,829
AVG SELL PX
$2.62
TRADE KIND
SHOWING 21 / 21
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 15 pending
Forward-return performance of every backtestable P/S trade by Benjamin Halladay, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+70.00%-1.31%+0.84%-2.15%-4.86%
14d10+50.00%-3.50%+0.35%-3.85%-5.41%
30d10+70.00%-5.16%+1.55%-6.71%-12.12%
60d10+50.00%+9.07%+2.60%+6.46%-2.44%
90d10+50.00%+13.04%+3.59%+9.45%-13.17%
180d10(1 pending)+44.44%+62.99%+10.08%+52.91%+5.26%
1y10(4 pending)+0.00%+89.12%+19.77%+69.34%+56.93%
2y10(10 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ESPR · 702,829 shares · as of Jun 17, 2026
0180,007360,013540,020720,0262023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 10 buys / 11 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
10,773$3.16$34.0K702,829Jun 17, 2026Jun 18, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
6,424$2.71$17.4K713,602Mar 17, 2026Mar 18, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
247,430720,026Mar 13, 2026Mar 16, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
221,270221,270Mar 13, 2026Mar 16, 2026View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,337$3.67$26.9K467,525Dec 17, 2025Dec 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,046$2.81$19.8K474,862Sep 17, 2025Sep 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
11$1.12$12474,462Jul 17, 2025Jul 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,229$1.15$8.3K474,473Jun 17, 2025Jun 18, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
8$0.96$8481,702Apr 17, 2025Apr 21, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,535$1.48$5.2K481,710Mar 18, 2025Mar 19, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
238,000485,245Mar 14, 2025Mar 17, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
213,000213,000Mar 14, 2025Mar 17, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
11$1.86$20240,671Feb 19, 2025Feb 20, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
9$2.27$20240,682Jan 17, 2025Jan 21, 2025View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,245$2.42$7.9K240,691Dec 17, 2024Dec 18, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Mar 14, 2024Mar 15, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
170,000243,936Mar 14, 2024Mar 15, 2024View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
39,00039,000Mar 14, 2023Mar 15, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,20073,936Mar 14, 2023Mar 15, 2023View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
66,00066,000Dec 9, 2022Dec 12, 2022View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
44,00063,771Dec 9, 2022Dec 12, 2022View →
Other insiders · ESPR
Loading peer insiders…
About this filer
CIK 0001953943
ROLE
Chief Financial Officer
PRIMARY
ESPR
COMPANIES
1
ACTIVE SINCE
Dec 2022
MARKETPEEL · /INSIDER/0001953943DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback